Apollomics APLM
NASDAQ APLM
$23.86 -1.02 (-4.04%)
As of: Sep 10, 2026 · 11:04 AM EDT

Apollomics (APLM) Other Non-Current Assets (2021 - 2025)

Apollomics' (APLM) quarterly Other Non-Current Assets came in at $51.3 million in Q4 2025, up 695.21% year-over-year from $6.5 million in Q4 2024, and up 695.21% quarter-over-quarter from $6.5 million in Q4 2024.

Analysis

Apollomics (APLM) Other Non-Current Assets (2021 - 2025) Analysis & Trends

Apollomics (APLM) has reported Other Non-Current Assets for 5 consecutive years, with $51.3 million the latest figure, recorded in Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 695.21% year-over-year to $51.3 million in Q4 2025; TTM through Dec 2025 was $51.3 million, a 695.21% increase from a year earlier, with the FY2025 full-year figure at $51.3 million, up 695.21% from the prior year.
  • Other Non-Current Assets was $51.3 million for Q4 2025 at Apollomics, up from $6.5 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $72.5 million in Q4 2021 and troughed at $6.5 million in Q4 2024.
  • A 5-year average of $36.7 million and a median of $41.2 million in 2023 frame the typical range for Other Non-Current Assets.
  • Across the five-year window, Other Non-Current Assets tumbled 75.53% in 2024 and soared 695.21% in 2025, its largest moves.
  • Over 5 years, Other Non-Current Assets stood at $72.5 million in 2021, then slumped by 40.08% to $43.4 million in 2022, then tumbled by 39.29% to $26.4 million in 2023, then plunged by 75.53% to $6.5 million in 2024, then soared by 695.21% to $51.3 million in 2025.
  • The last three Other Non-Current Assets figures came in at $51.3 million (Q4 2025), $6.5 million (Q4 2024), and $15.8 million (Q2 2024), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 12.98 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 4.75 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 1.25 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 2.31 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 124.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 618.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 65.13 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 831.80 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 29.59 Mn
10 Apollomics 34.50 Mn 31.23 Mn - 51.32 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 51.32 Mn
Dec 31, 2024 6.45 Mn
Jun 30, 2024 15.76 Mn
Dec 31, 2023 26.37 Mn
Jun 30, 2023 41.24 Mn
Dec 31, 2022 43.43 Mn
Dec 31, 2021 72.48 Mn